These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 1688625)

  • 1. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
    Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
    J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice.
    Roivainen M; Piirainen L; Hovi T
    Vaccine; 1993; 11(7):713-7. PubMed ID: 7688171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.
    Roivainen M; Hovi T
    J Virol; 1987 Dec; 61(12):3749-53. PubMed ID: 2824812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
    Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
    J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.
    Roivainen M; Hovi T
    J Virol; 1988 Sep; 62(9):3536-9. PubMed ID: 2841503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic sites of poliovirus type 3 eliciting IgA monoclonal antibodies in orally immunized mice.
    Buttinelli G; Ruggeri FM; Marturano J; Novello F; Donati V; Fiore L
    Virology; 2001 Mar; 281(2):265-71. PubMed ID: 11277698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Principal and subsidiary antigenic sites of VP1 involved in the neutralization of poliovirus type 3.
    Minor PD; Evans DM; Ferguson M; Schild GC; Westrop G; Almond JW
    J Gen Virol; 1985 May; 66 ( Pt 5)():1159-65. PubMed ID: 2582084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.
    van der Werf S; Briand JP; Plaué S; Burckard J; Girard M; Van Regenmortel MH
    Res Virol; 1994; 145(6):349-59. PubMed ID: 7535942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of monoclonal antibodies for the identification of the antigenic site for poliovirus neutralization.
    Minor PD; Schild GC; Evans D; Ferguson M; Almond J
    Dev Biol Stand; 1984; 57():171-5. PubMed ID: 6084608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactivity of anti-peptide and anti-poliovirus type 3 monoclonal antibodies with synthetic peptides.
    Ferguson M; Reed SE; Minor PD
    J Gen Virol; 1986 Nov; 67 ( Pt 11)():2527-31. PubMed ID: 2431104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a T-cell epitope adjacent to neutralization antigenic site 1 of poliovirus type 1.
    Leclerc C; Deriaud E; Mimic V; van der Werf S
    J Virol; 1991 Feb; 65(2):711-8. PubMed ID: 1702841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines.
    Zhaori G; Sun M; Faden HS; Ogra PL
    J Infect Dis; 1989 Jun; 159(6):1018-24. PubMed ID: 2470831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies reactive with different sites of N and H antigenic particles of poliovirus.
    Taniguchi K; Urasawa S; Urasawa T
    J Gen Virol; 1983 Dec; 64 ( Pt 12)():2803-8. PubMed ID: 6198442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
    J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenic analysis of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Schild GC
    Dev Biol Stand; 1984; 57():151-5. PubMed ID: 6098495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.
    Blondel B; Crainic R; Fichot O; Dufraisse G; Candrea A; Diamond D; Girard M; Horaud F
    J Virol; 1986 Jan; 57(1):81-90. PubMed ID: 2416957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic characterization of poliovirus type 3 using monoclonal antibodies.
    Ferguson M; Minor PD; Magrath DI; Spitz M; Schild GC
    Rev Infect Dis; 1984; 6 Suppl 2():S510-3. PubMed ID: 6204368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of humoral response to a 12-amino-acid site on the poliovirus virion.
    Icenogle JP; Minor PD; Ferguson M; Hogle JM
    J Virol; 1986 Oct; 60(1):297-301. PubMed ID: 3018295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of monoclonal antibodies prepared with Sabin vaccine viruses for the characterization of poliovirus strains isolated in Canada.
    Wachmann B; Henning D; Armstrong R; Boucher DW; Contreras G; Furesz J
    Dev Biol Stand; 1984; 57():141-9. PubMed ID: 6084605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I.
    Murray MG; Bradley J; Yang XF; Wimmer E; Moss EG; Racaniello VR
    Science; 1988 Jul; 241(4862):213-5. PubMed ID: 2838906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.